Hopes high around the world for AI-designed flu vaccine

From the U.S. by way of the Land Down Under comes a “turbo-charged” flu vaccine created by AI.

The project’s lead researcher, Nikolai Petrovsky of Flinders University in Australia, tells Britain’s Daily Telegraph that America’s National Institute of Allergy and Infectious Diseases is recruiting around 240 volunteers willing to give it a go.

These co-pioneers will make the vaccine the first AI-designed drug to be tested on humans, he points out.

“AI has been progressively used in clinical decision-making—which drugs should I use for which patient,” Petrovsky says. “But drug design has been considered such a difficult thing to do it was thought to be beyond the capability of current AI. But we’ve shown that we can do it.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup